TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19272808

Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (splint, heat, and exercise)
Number of subjects: 120
Study: 17289855

Group type: EXPERIMENTAL
Intervention: Bilateral eccentric overload strength training using the Bromsman device twice a week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unilateral eccentric body load training using a decline board twice a week
Number of subjects: 20
Study: 15336780

Group type: EXPERIMENTAL
Intervention: MART-1(27-35) peptide-pulsed autologous APC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAGE-1(161-169) peptide-pulsed APC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed APC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-vaccine PBL
Number of subjects: 0
Study: 11148437

Group type: EXPERIMENTAL
Intervention: Lansoprazole-based triple therapy for 7 days
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 9565943

Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high intensity shuttle run (PHISR)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Shuttle-run (SR)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treadmill run (TR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 8
Study: 8929937

Group type: EXPERIMENTAL
Intervention: Willingness for treatment
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Treatment tenure
Number of subjects: 494
Study: 2780404

Group type: EXPERIMENTAL
Intervention: Winningham Aerobic Interval Training (WAIT) exercise program, 60%-85% of maximal heart rate for 20-30 minutes, 3 times per week, for 10-12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise treatment (Control Group)
Number of subjects: 24
Study: 329423

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (0.022 mg/kg and 0.044 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 10
Study: 31818699

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (10-35 mg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film
Number of subjects: 109
Study: 31761524

Group type: EXPERIMENTAL
Intervention: NSA‐12 (Negative Symptom Assessment-12)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: NSA‐16 (Negative Symptom Assessment-16)
Number of subjects: 274
Study: 27858282

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (n=240)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Wait-list control condition (n=239)
Number of subjects: 479
Study: 26472122

Group type: EXPERIMENTAL
Intervention: Low-dose X-ray system with advanced real-time image processing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reference X-ray system
Number of subjects: 50
Study: 23196311

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 30
Study: 21311578

Group type: EXPERIMENTAL
Intervention: VivaGel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19811649

Group type: EXPERIMENTAL
Intervention: IPTp/SP
Number of subjects: 648

Group type: COMPARATOR
Intervention: CWC/CQ
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: IPTp/CQ
Number of subjects: 648
Study: 16507327

Group type: EXPERIMENTAL
Intervention: Aprinocarsen (2mg/kg/day continuous iv infusion for the first 14 days of each cycle), combined with gemcitabine (1,250 mg/m² on days 1 and 8) and carboplatin (AUC 5 on day 1 every 21 days).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (without aprinocarsen).
Number of subjects: 36
Study: 14747106

Group type: EXPERIMENTAL
Intervention: TachoComb (TC)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard treatment (suturing)
Number of subjects: 189
Study: 11757472

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 24
Study: 9164203

Group type: EXPERIMENTAL
Intervention: Six cycles of standard adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Number of subjects: 488

Group type: COMPARATOR
Intervention: One cycle of perioperative CMF therapy
Number of subjects: 488
Study: 8394880

Group type: EXPERIMENTAL
Intervention: ImuVert and radiation therapy (RT)
Number of subjects: 15
Study: 6691885

Group type: EXPERIMENTAL
Intervention: Group A (information about side-effects) and Group B (information about beneficial effects) combined
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group B (information about beneficial effects)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (no information)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group A (information about side-effects)
Number of subjects: 120
Study: 30513463

Group type: EXPERIMENTAL
Intervention: CASEL School Guide implementation model
Number of subjects: 14
Study: 29864779

Group type: EXPERIMENTAL
Intervention: Vorapaxar (10 mg initial dose, potentially an additional 10 mg based on aggregometry)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 16
Study: 27583648

Group type: EXPERIMENTAL
Intervention: Golf-Specific Resistance Training (GSRT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both TRAD and GSRT
Number of subjects: 45
Study: 24125514

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional polypectomy
Number of subjects: 70
Study: 22049096

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for six months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metformin 850 mg twice daily for six months
Number of subjects: 31
Study: 19575048

Group type: EXPERIMENTAL
Intervention: Power Toothbrush (PT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 109
Study: 17172551

Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional overground mobility intervention (CONT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combined intervention (BWSTT and CONT)
Number of subjects: 145
Study: 16551284

Group type: EXPERIMENTAL
Intervention: Hemodialysis dose defined by K/DOQI guidelines (spKt/V of 1.2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis dose defined by European guidelines (spKt/V of 1.4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalization of dialysis dose for low molecular weight water-soluble solutes (urea)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of spKt/V or eKt/V for routine monitoring of hemodialysis dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysis dose dependent on gender
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysis dose for middle molecules in clinical practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysis dose for more frequent hemodialysis treatment strategies
Number of subjects: 0
Study: 15451901

Group type: EXPERIMENTAL
Intervention: Insulin glulisine/NPH (n = 435)
Number of subjects: 876

Group type: COMPARATOR
Intervention: Regular human insulin (RHI)/NPH (n = 441)
Number of subjects: 876
Study: 10633218

Group type: EXPERIMENTAL
Intervention: High dose infusion of insulin (HDT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low dose infusion of insulin (LDT)
Number of subjects: 10
Study: 8659772

Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen, 2 x 800 mg (n = 57)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 115
Study: 2058222

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theophylline administered via endoscope into the colon transversum
Number of subjects: 8
Study: 6097457

Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analogue (40 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31246579

Group type: EXPERIMENTAL
Intervention: Group A (2000-2500 g)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Group B (2500-3000 g)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Group C (3000-3500 g)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Group D (3500-4000 g)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Males vs Females
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2000
Study: 28810909

Group type: EXPERIMENTAL
Intervention: Eosinophil-guided corticosteroid-sparing therapy (prednisolone not administered if eosinophil level < 0.3 × 10^9 cells/L)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard care (5-day course of high-dose systemic corticosteroids)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Eosinophil-guided corticosteroid-sparing therapy
Number of subjects: 320
Study: 25504427

Group type: EXPERIMENTAL
Intervention: Flexible breast compression paddle (FP)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Rigid breast compression paddle (RP)
Number of subjects: 288
Study: 22821925

Group type: EXPERIMENTAL
Intervention: US-guided pararadicular injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT-controlled interventions
Number of subjects: 40
Study: 21082298

Group type: EXPERIMENTAL
Intervention: Oral caffeine 200 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral caffeine 400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 90
Study: 19118324

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Haloperidol (5-15 mg/day)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 485
Study: 16511899

Group type: EXPERIMENTAL
Intervention: Decision aid (Adjuvant!)
Number of subjects: 405
Study: 15195725

Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam restorations (self-threading stainless steel pins)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations (filled, 4-META-based bonding resin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 60
Study: 11242608

Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide, 500 mg twice a day for 2 years
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (asthma patients not requiring glucocorticoid treatment)
Number of subjects: 29
Study: 9060365

Group type: EXPERIMENTAL
Intervention: Venoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0
Study: 8452386

Group type: EXPERIMENTAL
Intervention: l-leucovorin 250 mg/m2 weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: l-leucovorin 100 mg/m2 for 5 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: l-leucovorin 10 mg/m2 for 5 consecutive days
Number of subjects: 0
Study: 3512663

Group type: EXPERIMENTAL
Intervention: Slo-bid capsules
Number of subjects: 20

Group type: COMPARATOR
Intervention: Theo-Dur tablets
Number of subjects: 20
Study: 31745223

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study: 30403730

Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study: 27604334

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL-148)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 69
Study: 24648266

Group type: EXPERIMENTAL
Intervention: Bone turnover biomarkers (serum bone‐specific alkaline phosphatase (BALP), osteocalcin (OC), urinary N‐telopeptide of type I collagen indexed to creatinine (NTX/Cr))
Number of subjects: 418

Group type: COMPARATOR
Intervention: ALL-related treatments
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Bone turnover
Number of subjects: 418
Study: 22674095

Group type: EXPERIMENTAL
Intervention: Echocardiographic measurement of intercommissural diameter (EBRS group, n = 43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Height-based balloon reference sizing (HBRS group, n = 43)
Number of subjects: 86
Study: 20979455

Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (100-μg dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (50-μg dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (50-μg and 100-μg dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18568841

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16026659

Group type: EXPERIMENTAL
Intervention: Advice to rest or take it easy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Advice on simple symptom management
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: No specific advice
Number of subjects: 71
Study: 11951579

Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream (Dolgit cream), applied in a 10-cm strip t.i.d. for 7 days, each strip containing approximately 200 mg ibuprofen.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream, applied in the same manner as the ibuprofen cream.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Secondary endpoints including pain at rest, pain on pressure, Lequesne index, and overall assessment.
Number of subjects: 100
Study: 9686453

Group type: EXPERIMENTAL
Intervention: Equal status - different dimensions condition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Common in-group identity model
Number of subjects: 6
Study: 8090332

Group type: EXPERIMENTAL
Intervention: Oral 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral and intraperitoneal 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study: 2638641

Group type: EXPERIMENTAL
Intervention: Econazole (1% hair-shampoo)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Zinc-pyrithione shampoo
Number of subjects: 70
Study: 51188

Group type: EXPERIMENTAL
Intervention: Hepatitis-B immunoglobulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal human immunoglobulin (Control)
Number of subjects: 0
Study: 31571522

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 0
Study: 30912719

Group type: EXPERIMENTAL
Intervention: CT examinations with intravenous contrast agent (n = 4263)
Number of subjects: 20374

Group type: COMPARATOR
Intervention: CT examinations without intravenous contrast agent (n = 16,111)
Number of subjects: 20374

Group type: EXPERIMENTAL
Intervention: Fully automated L1 Hounsfield unit measurement (n = 11,270)
Number of subjects: 20374

Group type: COMPARATOR
Intervention: Manual L1 Hounsfield unit measurement (n = 9104)
Number of subjects: 20374
Study: 28820930

Group type: EXPERIMENTAL
Intervention: Minimally invasive strabismus surgery (MISS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional strabismus surgery (limbal technique)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 25933487

Group type: EXPERIMENTAL
Intervention: Supplementation with 900 mg of eicosapentaenoic acid plus 680 mg of docosahexaenoic acid for 4 weeks
Number of subjects: 80
Study: 24156966

Group type: EXPERIMENTAL
Intervention: pPCI + RIPC (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pPCI (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: pPCI + RIPC
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pPCI
Number of subjects: 100
Study: 22091574

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19748293

Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration (BI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IANB plus periodontal ligament (PDL) injection
Number of subjects: 57
Study: 17014554

Group type: EXPERIMENTAL
Intervention: Upper extremity AVF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-AVF upper extremity (control)
Number of subjects: 30
Study: 15183026

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10763910

Group type: EXPERIMENTAL
Intervention: Phentermine hydrochloride therapy plus a low energy diet (5040 kJ/d)
Number of subjects: 47
Study: 8973780

Group type: EXPERIMENTAL
Intervention: Lacidipine-based treatment
Number of subjects: 1965

Group type: COMPARATOR
Intervention: Beta-blocker (atenolol)-based treatment
Number of subjects: 1965
Study: 1611652

Group type: EXPERIMENTAL
Intervention: Cefprozil (administered once daily for ten days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor (administered three times a day for ten days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefprozil and Cefaclor
Number of subjects: 0
Study: 6142351

Group type: EXPERIMENTAL
Intervention: 10 mg dose of metaraminol infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prophylactic colchicine therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29099978

Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) during low glycemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo) during low glycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) during high glycemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo) during high glycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) after 60 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo) after 60 minutes
Number of subjects: 10
Study: 28288977

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Moderate risk
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: High risk
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Very high risk
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Low risk
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Major CVD events
Number of subjects: 5966
Study: 25767259

Group type: EXPERIMENTAL
Intervention: GSK‐1614235 (20 mg) premeal dosing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23795579

Group type: EXPERIMENTAL
Intervention: Alumina heads
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cobalt-chrome heads
Number of subjects: 39
Study: 21259280

Group type: EXPERIMENTAL
Intervention: Early and intensive statin therapy (60 mg immediately and 40 mg/day atorvastatin)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Conventional statin therapy (10 mg/day atorvastatin)
Number of subjects: 586
Study: 19178799

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulante for 3 weeks after FESS
Number of subjects: 71

Group type: COMPARATOR
Intervention: No antibiotic after FESS (Control group)
Number of subjects: 71
Study: 16618013

Group type: EXPERIMENTAL
Intervention: 40 mg DHEC (Almirid 40 mg test T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 x 20 mg DHEC (Almirid 20 mg reference R)
Number of subjects: 24
Study: 12740740

Group type: EXPERIMENTAL
Intervention: Shot putter 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Shot putter 1
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untrained brother of shot putter 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Shot putter 1 after 3 years of active detraining
Number of subjects: 3
Study: 10576464

Group type: EXPERIMENTAL
Intervention: Paroxetine (10 to 40 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Citalopram (10 to 40 mg daily)
Number of subjects: 26
Study: 8963838

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 71

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Peritoneal carcinomatosis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Negative cytology
Number of subjects: 71
Study: 1724577

Group type: EXPERIMENTAL
Intervention: Aprotinin (high dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6359887

Group type: EXPERIMENTAL
Intervention: Metoprolol (a beta 1‐adrenergic antagonist)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-dose terbutaline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Infusion dosages above 40 micrograms/min
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined beta‐mimetics and glucocorticoids
Number of subjects: 17
Study: 3890795

Group type: EXPERIMENTAL
Intervention: D-Penicillamine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 30318973

Group type: EXPERIMENTAL
Intervention: Average MVPA per day
Number of subjects: 807

Group type: COMPARATOR
Intervention: MVPA assessed over 7 days
Number of subjects: 807
Study: 26513581

Group type: EXPERIMENTAL
Intervention: 3-D bone models
Number of subjects: 58